Enliven Therapeutics, Inc. (ELVN)
| Market Cap | 1.54B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -97.21M |
| Shares Out | 59.35M |
| EPS (ttm) | -1.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,665,918 |
| Open | 23.58 |
| Previous Close | 23.25 |
| Day's Range | 23.27 - 29.98 |
| 52-Week Range | 13.30 - 29.98 |
| Beta | 1.20 |
| Analysts | Strong Buy |
| Price Target | 41.00 (+57.69%) |
| Earnings Date | Nov 12, 2025 |
About ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The c... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ELVN stock is "Strong Buy." The 12-month stock price target is $41.0, which is an increase of 57.69% from the latest price.
News
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars
Enliven Therapeutics Inc. (NASDAQ: ELVN) stock is trading higher on Thursday, with a session volume of 6.61 million compared to the average volume of 631.52 thousand as per data from Benzinga Pro.
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts ELVN-001 continues to demonstrate a favorable s...
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors Building on positive data reported in 202...
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molec...
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer Co-Founder Sam Kintz will assume a new position as Hea...
Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy
Enliven Therapeutics remains overvalued relative to its early-stage pipeline progress and current financials. ELVN-001 shows promising safety and efficacy signals in heavily pretreated CML patients, w...
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML Remains on track to initiate Phase 3 pivotal trial of ELVN-001 in 2026 Strong balance sheet with ...
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting
BOULDER, Colo. , Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety a...
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BOULDER, Colo. , June 16, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress
Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::...
Enliven Therapeutics to Present at Upcoming Investor Conferences
BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of ...
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26%...
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress
Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::A...
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
Final Trade: CVX, XLE, ELVN, COF
The final trades of the day with the Fast Money traders.
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong b...
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
BOULDER, Colo. , Feb. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
Biotech walks a 'tightrope' amid unclear funding, regulations
Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street se...
Enliven's Early Data Stands Out From Peers
Enliven Therapeutics' ELVN-001 shows promising interim data, achieving a 44% major molecular response rate in heavily pre-treated CML patients within 12 weeks. ELVN-001 targets the BCR-ABL gene fusion...
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
BOULDER, Colo. , Nov. 7, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of...
Why Enliven is this analyst's top biotech stock pick
Salim Syed, Mizuho Americas managing director and senior analyst, joins the latest edition of Good Buy or Goodbye to discuss his top and bottom picks in the pharmaceutical industry. Syed points to Enl...
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Updated Phase 1 data presented at ESH-iCMLf 26 th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, whi...